Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs Biosimilar Ranibizumab in Diabetic Retinopathy
NCT07520045Recruiting
- Sponsor
- Osijek University Hospital Centre
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of faricimab in diabetic retinopathy (DR) and diabetic macular edema (DME) (2 arms), sponsored by Osijek University Hospital Centre. Primary endpoint: Comparison of OCT and OCTA biomarkers associated with early anatomical treatment response. Started Mar 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
diabetic retinopathy (DR)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07520045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520045.